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Abstract: Microalgae contain a multitude of nutrients and can be grown sustainably. Fucoxanthin,
a carotenoid from Phaeodactylum tricornutum, could have beneficial health effects. Therefore, we
investigated the anti-inflammatory, antioxidative and antiproliferative effects of fucoxanthin derived
from this diatom in vitro. The effects of purified fucoxanthin on metabolic activity were assessed
in blood mononuclear cells and different cell lines. In cell lines, caspase 3/7 activity was also
analyzed. Nitrogen monoxide release and mRNA-expression of proinflammatory cytokines were
measured. For antioxidant assays, cell free assays were conducted. Additionally, the antioxidant
effect in neutrophils was quantified and glutathione was determined in HeLa cells. The results
show that neither did fucoxanthin have anti-inflammatory properties nor did it exert cytotoxic
effects on mononuclear cells. However, the metabolic activity of cell lines was decreased up to 58%
and fucoxanthin increased the caspase 3/7 activity up to 4.6-fold. Additionally, dose-dependent
antioxidant effects were detected, resulting in a 63% decrease in chemiluminescence in blood
neutrophils and a 3.3-fold increase in the ratio of reduced to oxidized glutathione. Our studies show
that fucoxanthin possesses antiproliferative and antioxidant activities in vitro. Hence, this carotenoid
or the whole microalgae P. tricornutum could be considered as a food or nutraceutical in human
nutrition, showcasing beneficial health effects.
Keywords: microalgae; Phaeodactylum tricornutum; fucoxanthin; antioxidative; antiproliferative
1. Introduction
Microalgae are microscopic small unicellular organisms that are abundant in various habitats
around the globe. They can be cultured in open ponds or photobioreactors without the use of arable
land and thus represent a promising sustainable alternative to plant-based proteins. They do not only
produce high amounts of proteins but are also a good source for fatty acids, and vitamins, which can
provide health promoting effects in a human diet. Hence, they can serve as novel functional foods or
be incorporated into existing food products [1,2].
The unicellular pennate diatom Phaeodactylum tricornutum exists in three different morphotypes
and its genome has been already fully sequenced [3]. The diatom contains a multitude of different
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components that could provide health beneficial effects. These include the omega-3 fatty acid
eicosapentaenoic acid (EPA), polyphenols like (epi-) catechin and oxygenated carotenoids like
fucoxanthin [4–8]. Fucoxanthin, a major marine carotenoid, is located in the thylakoids of chloroplasts
and forms a light harvesting complex (LHC) with chlorophyll a/c [9,10]. It was shown in several studies,
that fucoxanthin from macroalgae possesses health-conducive effects, including anti-inflammatory,
antioxidant, antiobesity and anticancer activities [11–15]. Since most of these studies used fucoxanthin
derived from macroalgae, only little is known about the health-beneficial effects of fucoxanthin derived
from P. tricornutum, although this microalga was shown to have a high content of fucoxanthin between
16.5 to 26.1 mg per gram dry matter (dm) [16,17]. Thus, diatom biomass can contain up to ten
times more fucoxanthin than macroalgae. Additionally, diatoms, different from macroalgae, can be
cultivated indoors and outdoors not only during specific seasons but all around the year with a high
biomass productivity [18]. It is already demonstrated that they can be produced in various types of
different closed photobioreactors, like bubble columns and flat panel airlift bioreactors [19–21]. Hence,
P. tricornutum might be a suitable source for the commercial production of fucoxanthin.
The prevalence of diseases linked to oxidative stress and inflammation is constantly increasing in
developed countries [22–24]. The occurrence of those diseases can also be linked to the emergence
of cancer [25,26]. Therefore, research is trying to identify new compounds that could be used to
reduce inflammation, oxidative stress, and the viability of cancer cells. Fucoxanthin derived from
P. tricornutum might be used as a new nutraceutical, if it also exhibits the health beneficial effects that
were already shown for the carotenoid derived from macroalgae.
2. Materials and Methods
2.1. Cultivation of Microalgae and Fucoxanthin Extraction
P. tricornutum UTEX 640 was cultivated in 180 L Flat-Panel-Airlift photobioreactors in an outdoor
pilot scale plant located at the Fraunhofer Center for Chemical-Biotechnological Processes CBP in
Leuna, Germany. Modified Mann and Myers medium was used as culture medium as described
in Meiser et al. [19,27]. The biomass was disrupted using stirred ball milling (PML-2, Bühler) and
freeze-drying prior to fucoxanthin extraction. The cell disruption and extraction method were
previously described in detail in Derwenskus et al. [17]. Briefly, Fucoxanthin was extracted from the
disrupted biomass by pressurized liquid extraction (ASE 350, Thermo-Fisher) for a static extraction
time of 20 min at 100 ◦C and 100 bar using adequate subcritical organic solvents (described in [28]).
Subsequently, the fucoxanthin was purified by multiple separation steps using filters (0.25 µm)
consisting of polytetrafluoroethylene to a final purity of 99.2% (w/w) (HPLC). It was compared to a
commercial fucoxanthin standard (16337, Sigma-Aldrich) using UHPLC-MS.
It was compared to a commercial fucoxanthin standard (16337, Sigma-Aldrich) using UHPLC-MS.
2.2. Determination of Fucoxanthin by HPLC and UHPLC-MS
Fucoxanthin was quantified using the HPLC method described by Gille et al. [28] with slight
modifications. Briefly, the purified fucoxanthin was resolved in pure ethanol with BHT (250 mg/L)
and compared to a commercial analytical standard (16337, Sigma-Aldrich, St. Louis, MO, USA) using
reverse-phase HPLC with a Suplex pKb 100 column (5 µm, 250 × 4.6mm, Supelco, Bellefonte, PA, USA).
Samples (injection volume 5 µL) were analyzed using a HPLC (1200 Infinity, Agilent, Santa Clara,
CA, USA) equipped with a multi-wavelength UV detector at 450 nm and a flow rate of 1 mL/min.
The gradient used for the method is described in detail elsewhere [29].
Additionally, fucoxanthin from P. tricornutum was analyzed and compared to the commercial
standard by UHPLC-DAD (1290 Infinity, Agilent Technologies) using a Zorbax Eclipse Plus C18
(2.1 × 50 mm) column with a particle size of 1.8 µm. Mobile phase A contained water with 0.1% formic
acid and mobile phase B consisted of methanol with 0.1% formic acid. The gradient used is shown
in Table 1. The fucoxanthin was detected at 450 nm and analyzed in a mass spectrometer (LTQ XL,
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Thermo Scientific) using ESI in full scan mode from 200 to 1000 m/z at a temperature of 275 ◦C and
−9.0 V. The m/z values (see supplementary material, S1) were compared to the analytical standard and
to literature [30].
Table 1. Solvent gradient for the UHPLC-MS-Method used in this study. Mobile phase A consisted of
water with 0.1% formic acid and mobile phase B was methanol with 0.1% formic acid.
Time [min] Mobile Phase A [%] Mobile Phase B [%]
0 70 30
8 3 97
11 3 97
11.1 70 30
14 70 30
2.3. Isolation of Human Primary Blood Cells Band Cell Cultures
Anticoagulated blood was collected from healthy volunteers, approved by the local ethics
committee (F-2015-064, Landesärztekammer Baden-Württemberg). Isolation of polymorphonuclear
leukocytes (PML) and peripheral blood mononuclear cells (PBMCs) via dextran sedimentation and
density gradient centrifugation was conducted as previously described by El Benna & Dang (2007) [30]
and Neumann et al. (2018) [31]. PMLs were resuspended in DPBS, PBMCs in RPMI medium with
10% fetal calf serum and 1% penicillin / streptomycin. HepG2 cells were provided by the Max
Rubner-Institute (Karlsruhe, Germany). RAW 264.7, HepG2, Caco-2 and HeLa cells were cultured in
DMEM with 10% fetal calf serum and 1% penicillin / streptomycin.
2.4. Metabolic Activity
Metabolic activity was assessed using the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT). PBMCs (3 × 105 cells per well) and RAW 264.7 cells (1 × 104 cells
per well) were incubated with fucoxanthin (0.1, 1, 10 and 50 µg/mL), β-carotene (1 µg/mL), dimethyl
sulfoxide (DMSO, 0.1%) as solvent control or DMSO (5%) as positive control for 24 h. Subsequent,
MTT assay was conducted as previously described [31].
2.5. Antiinflammatory Assays
Nitric oxide (NO) production in RAW 264.7 cells was measured using the Griess assay. Therefore,
5 × 105 cells were treated with fucoxanthin (0.1 and 1 µg/mL) or β-carotene (1 µg/mL) and stimulated
with lipopolysaccharide (LPS, 1 µg/mL) for 24 h. The level of NO was measured using the Griess
reaction, as previously described [32].
The effects of fucoxanthin on the LPS-induced mRNA expression of the cytokines interleukin-
(IL-)1β, IL-6, tumor necrosis factor α (TNF-α) and the enzyme cyclooxygenase-2 (COX-2) in PBMCs
was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Cells were incubated
with fucoxanthin (0.1, 1 or 10 µg/mL), β-carotene (1 µg/mL) or DMSO (0.1%) as solvent control for 24 h.
Cells were stimulated with LPS (1 µg/mL) for 6 h. The mRNA expression was measured as formerly
described [31].
2.6. Antioxidant Assays
Total phenolics content (TPC) was determined using the Folin-Ciocalteu method [33] with minor
modifications. In a 96-well microplate, 30 µL of fucoxanthin (0.1, 1 or 10 µg/mL) were mixed with
150 µL Folin-Ciocalteu reagent (diluted 1/10 in water) and 120 µL sodium carbonate solution (75 g/L).
To obtain an individual blank, samples were mixed with 120 µL sodium carbonate solution and 150 µL
water. After 2 h in the dark at room temperature, the absorbance was measured at 765 nm with a
BioTek Synergy HT plate reader (BioTek Instruments, Winooski, VT, USA). Gallic acid was used to
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establish a calibration curve (30–580 µM) and results are expressed as gallic acid equivalents (GAE) per
gram dry matter (dm).
The ferric reducing antioxidant power (FRAP) assay was performed in accordance to the method
of Benzie and Strain [34]. An individual blank was measured for each sample. Ferrous sulphate
solutions were used for calibration (50–1000 µM) and the results are expressed as mmol Fe2+ per
gram dm.
For the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay a calibration curve was obtained by using
DPPH concentrations in the range of 0-100 µM. A DPPH solution was freshly prepared in methanol.
150 µL DPPH (0.1 MM) were mixed with 50 µL fucoxanthin (0.1, 1, 10 or 50 µg/mL), 150 µL methanol
instead of DPPH were used for blank measurement. The percentage inhibition was calculated using
the following formula:
%Inhibition = (ODDPPH − ODSample)/ODDPPH × 100
The half maximal inhibitory concentration (IC50) was calculated by linear regression, plotting the
percentage inhibition against the different extract concentrations.
The glutathione (GSH) to glutathione disulfide (GSSG) ratio as a marker for oxidative stress was
determined using the GSH/GSSG-Glo™ Assay (Promega, Mannheim, Germany). 2 × 104 HeLa cells
were incubated with fucoxanthin (0.1, 1, 10 and 50 µg/mL), β-carotene (1 µg/mL), DMSO (0.1%) as
solvent control or menadione (40 µM) as control for 24 h.
2′,7′-dichlorofluorescin (DCF) fluorescence and ROS production using luminol chemiluminescence
were measured in human PMLs. For DCF fluorescence 100 µL of freshly drawn blood were incubated
with 2′,7′-dichlorofluorescin diacetate (20 µM) at 37 ◦C for 15 min. Lipopolysaccharide (10 ng/mL)
and fucoxanthin (0.1, 1, 10 or 50 µg/mL) or β-carotene (1 µg/mL) were added for 1 h at 37 ◦C. Cells
were then stimulated with N-formylmethionyl-leucyl-phenylalanine (fMLP, 500nM). The reaction was
stopped after 5 min by placing the samples on ice. After red blood cell lysis using the BD FACS lysing
solution according to the manufacturer’s instructions, DCF fluorescence was measured with a BD
FACS Canto II (BD Biosciences, Becton, Dickinson and Company, San Jose, CA, USA). The percentage
of fluorescent PMLs was calculated using the BD FACS Diva Software.
In luminol assays, PMLs were incubated with fucoxanthin (0.1, 1, 10 and 50 µg/mL), β-carotene
(1 µg/mL), DMSO (0.1%) as solvent control or menadione (40 µM) as control. The assay was conducted
as previously described [35] and cells were stimulated with phorbol 12-myristate 13-acetate (PMA,
100 ng/mL). Chemiluminescence was measured in a Berthold-Biolumat LB937 (Berthold Technologies
Co., Bad Wildbad, Germany) at 37 ◦C for 15 min. Percentage inhibition of luminescence was calculated
using the area under the curve (AUC) values.
2.7. Cytotoxic and Apoptotic Assays
MTT assays were conducted with Caco-2, HeLa and Hep G2 cells to assess cytotoxic activity
of fucoxanthin on cancer cells. Cells were incubated with fucoxanthin (0.1, 1, 10 and 50 µg/mL),
β-carotene (1 µg/mL), DMSO (0.1%) or staurosporine (1 µM) for 48 h, as described elsewhere [32].
For apoptotic properties, the caspase-glo®3/7 assay (Promega, Mannheim, Germany) was conducted
according to the manufacturer’s instructions.
2.8. Statistics
Data are expressed as mean ± standard error of the mean (SEM) in graphs or ± standard deviation
(SD) in tables. Graphs were generated using GraphPad Prism 5 (La Jolla, CA, USA), statistics were
done using IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, USA), graphs. Normal distribution was
tested using the Shapiro–Wilk test. One-way analysis of variance (ANOVA) was used to evaluate
statistic significant differences (p < 0.05) between groups. The equality of variances was tested utilizing
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Levene’s test. For equal variances, Tukey’s HSD post hoc test was used; for unequal variances,
Dunnett’s T3 post hoc test3.
3. Results
3.1. Metabolic Activity
For PBMCs, only the positive control with a final concentration of 5% DMSO led to a significant
decrease in metabolic activity analyzed using the MTT assay. Fucoxanthin up to a concentration
of 50 µg/ml did not influence the metabolic activity (Table 2). For RAW 264.7, however, a decrease
in metabolic activity was shown for the positive control and the highest fucoxanthin concentration
tested (50 µg/mL, Table 2). Hence, the following anti-inflammatory assays were only conducted with
non-cytotoxic concentrations.
Table 2. Effects of fucoxanthin from P. tricornutum, vehicle control (DMSO, 0.1%), positive control
(DMSO, 5%) and β-carotene on metabolic activity of PBMCs and RAW 264.7 cells. Data are presented
as mean ± SD (n = 4–6).
[µg/mL] Metabolic Activity [%]
PBMCs RAW 264.7
Vehicle control 100 100
Positive control 54.27 ± 4.23 ** 3.39 ± 3.02 ***
Fucoxanthin 50 104.7 ± 14.16 20.88 ± 6.33 **
10 98.76 ± 5.38 73.28 ± 9.60
1 95.25 ± 3.84 89.64 ± 13.76
0.1 88.35 ± 14.13 93.12 ± 5.09
β-carotene 1 87.65 ± 13.47 80.30 ± 13.09
Asterisks mark significant differences to vehicle control as analyzed by ANOVA with Dunnett’s T3 post hoc test
(*<0.05, ** <0.01, *** <0.001).
3.2. Antiinflammatory Effects
To analyze the anti-inflammatory effects of fucoxanthin, the NO production of RAW 264.7 cells
was measured, and mRNA-expressions of inflammatory cytokines were determined in PBMCs (Table 3).
Neither fucoxanthin nor β-carotene showed anti-inflammatory effects in the tested concentrations
(Table 3). Additionally, no pro-inflammatory effect was seen in unstimulated cells (Table 3).
Table 3. Effects of fucoxanthin from P. tricornutum, vehicle control (DMSO, 0.1%) and β-carotene on
relative mRNA expression of pro-inflammatory cytokines in PBMCs and on NO production in RAW
264.7 cells. Data are presented as mean ± SD (n = 5–7).
[µg/mL] IL-1β [%] IL-6 [%] TNFα [%] NO [µM]
PBMCs PBMCs PBMCs RAW 264.7
Vehicle control 100 100 100 59.66 ± 7.59
Fucoxanthin 10 110.1 ± 26.55 99.15 ± 26.14 160.4 ± 68.13 56.53 ± 6.58
1 97.65 ± 18.09 92.10 ± 22.18 133.3 ± 60.35 60.84 ± 7.65
0.1 101.3 ± 18.29 122.5 ± 32.23 133.9 ± 55.50 59.21 ± 7.69
β-carotene 1 75.07 ± 44.36. 104.2 ± 57.37 158.7 ± 80.90 59.84 ± 7.10
Vehicle control,
unstimulated 0.2 ± 0.1 0.1 ± 0.1 5.6 ± 5.7 0.0 ± 0.0
Fucoxanthin, unstimulated 10 0.3 ± 0.5 0.1 ± 0.04 5.1 ± 6.2 0.03 ± 0.1
β-carotene, unstimulated 1 0.2 ± 0.2 0.1 ± 0.2 3.8 ± 2.2 0.0 ± 0.0
No differences between stimulated groups and no differences between unstimulated groups were found by ANOVA
(p < 0.05). Abbreviations: IL interleukin; TNF tumor necrosis factor, NO nitrogen monoxide.
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3.3. Antioxidant Effects
Various assays were conducted to analyze the antioxidant properties of fucoxanthin. In the DPPH
assay, fucoxanthin had an IC50 value of 201.2 ± 21.4 µg/mL, while the value for ascorbic acid was
70.3 ± 18.7 µg/mL and for astaxanthin 79.32 ± 18.10 µg/mL. Due to low antioxidant effects, an IC50 for
β-carotene could not be calculated. Results of the FRAP assay show that fucoxanthin is equivalent to
64.74 ± 3.93 mmol Fe2+ per gram dm, β-carotene to 6.55 ± 0.33 and astaxanthin to 63.97 ± 6.79 mmol
Fe2+ per gram.
Neither fucoxanthin nor β-carotene showed effects on the DCF fluorescence of PMLs (data not
shown). Menadione decreased the GSH/GSSG ratio. However, according to statistical analysis this
change was not significant (p = 0.09). Fucoxanthin in the highest concentration (50 µg/mL) increased
the ratio significantly (Figure 1A). Lower concentrations, however, showed no effects. Luminol
chemiluminescence was measured to evaluate the antioxidant properties of fucoxanthin in PMLs.
The results are depicted in Figure 1B and show that menadione decreased the luminescence by 96%,
fucoxanthin by 63% at 50 µg/mL. The antioxidant effect is dose-response dependent.
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Figure 1. Effects of fucoxanthin from P. tricornutum on GSH to GSSG ratio in HeLa cells (A) and
on luminol chemiluminescence in freshly isolated PMLs (B) (n = 3–5). Different letters represent
significantly different groups (ANOVA followed by Tukey post hoc test for GSH/GSSG assay or with
Du nett’s T3 post hoc test for luminol chemiluminescence, p < 0.05). Abbreviations: GSH glutathione,
GSSG glutathione disulfide.
3.4. Cytotoxic and Apoptotic Effects
Fucoxanthin was able to reduce the metabolic activity of Hep G2, HeLa and Caco-2 cells in
a dose-dependent manner (Figure 2A–C). An inhibitory effect of up to 58% was measured in Hep
G2 cells. In HeLa and Caco-2 cells, the effect was stronger than that of the positive control with a
final concentration of 5% DMSO. In order to evaluate if the decrease in metabolic activity is linked
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to apoptosis, the caspase 3/7 activity was determined. The results show that fucoxanthin led to a
dose-dependent increase in caspase 3/7 activity (Figure 2D–F). A 4.6-fold increase in caspase activity
was measured in HeLa cells for the highest fucoxanthin concentration. 50 µg/mL of the carotenoid led
to a higher caspase 3/7 activity than 1µM staurosporine in all tested cell cultures.
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Figure 2. Effects of fucoxanthin from P. tricornutum on metabolic activity of HeLa (A), Caco-2 (B) and
HepG2 (C) cells (n = 4–6). Cells were incubated for 48 hours, DMSO (5%) was used as a positive control.
Caspase 3/7 activity as a marker for apoptosis was assessed in HeLa (D), Caco-2 (E) and HepG2 (F) cells
(n = 4). Here, staurosporine (1 µM) was used as a positive control. Different letters mark significant
differences (ANOVA followed by Tukey post hoc test for D or with Dunnett’s T3 post hoc test, p < 0.05).
4. Discussion
Fucoxanthin, a major marine carotenoid that is up to now obtained from macroalgae, was
successfully extracted from the microalgae P. tricornutum. In this study, we found that fucoxanthin
had no influence on the metabolic activity of PBMCs, which was also reported by Ishikawa et al. [36].
This leads to the assumption that fucoxanthin, up to concentrations of 50 µg/mL, has no cytotoxic
effects on these cells. However, the carotenoid had a cytotoxic effect on the mouse macrophage cell line
RAW 264.7 at 50 µg/mL. This is not concordant to a study by Islam et al. (2013), who only reported a
reduced cell viability at much higher doses of fucoxanthin [37].
This study found no effects of fucoxanthin on the NO production of LPS-stimulated RAW 264.7
cells. A study by Islam et al. (2013) supports these findings [37]. Authors showed anti-inflammatory
effects only at higher concentrations [37]. However, other studies were able to show a dose-dependent
inhibition of NO production by fucoxanthin at lower concentrations [12,38,39]. Here, we also reported
that the carotenoid had no effect on the mRNA-expression of pro-inflammatory cytokines in human
PBMCs. This is also not concordant to the study by Heo et al. (2010), who showed an inhibitory effect
on the mRNA expression in RAW 264.7 cells [12]. Yet, to date, no studies on the anti-inflammatory
effects of fucoxanthin on human primary blood cells have been published. It is noteworthy that all
mentioned studies utilized fucoxanthin extracted from seaweeds. Therefore, it can be assumed that the
carotenoid from P. tricornutum might have different effects or that the measured effects in other studies
are based on impurities resulting from extraction.
Fucoxanthin showed strong antioxidant effects in cell-free and cell-based assays. The IC50
concentration of fucoxanthin with 201 µg/mL in the DPPH assay was higher than that reported by
Sachindra et al. (2007) [40]. The higher values might be caused by differences in extraction or on the
origin of the carotenoid. As previously described, β-carotene showed no DPPH radical scavenging
activity [41]. Antioxidant effects of ascorbic acid, however, were stronger in FRAP and DPPH assays.
The FRAP assay revealed that the antioxidant effects of fucoxanthin extracted from P. tricornutum does
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not significantly differ from that of astaxanthin, a carotenoid with strong antioxidant effects derived
from the red algae Haematococcus pluvialis which is already successfully commercialized [42,43]. Both,
fucoxanthin as well as astaxanthin showed a strong antioxidant effect in the FRAP assay compared to
β-carotene.
In the DCF fluorescence assay, neither fucoxanthin nor β-carotene showed antioxidant effects
while the luminol assay revealed dose-dependent antioxidant properties of fucoxanthin. The DCF assay
is used for the intracellular detection of ROS, especially H2O2 [44]. Luminol, on the other hand, can
detect the sum of extra- and intracellular ROS, especially those generated by the myeloperoxidase [45].
Hence, it can be assumed that fucoxanthin is either inhibiting the myeloperoxidase activation or
quenching the bactericidal hypochlorite produced by this enzyme. Fucoxanthin was also able to
increase the GSH level in HeLa cells, which was already shown by a study in human keratinocytes [46].
GSH as an antioxidant is able to scavenge ROS; the ratio of GSH to GSSG is often used as a marker
for oxidative stress. A multitude of diseases is linked to a decreased GSH to GSSG ratio, including
Alzheimer’s and Parkinson’s disease [47–49]. Fucoxanthin could help to increase reduced GSH and
hence ameliorate the negative effects of oxidative stress.
Although fucoxanthin had no effect on the metabolic activity of human blood cells, a
dose-dependent influence on different carcinoma cell lines was shown. For Caco-2 cells and different
cell lines, this was already shown previously [50–52]. To analyze if the reduced metabolic activity
is linked to an increased apoptosis of cells, we also measured the caspase 3/7 activity. An increase
in activity was shown for all cells, leading to the conclusion that fucoxanthin from P. tricornutum
is able to induce apoptosis in different cancer cells. Kim et al. (2010) were able to show, that the
induced apoptosis is caused by the formation of ROS by fucoxanthin [51]. The authors state that the
production of intracellular H2O2 and superoxide in the carcinoma cells triggers the apoptosis. This is,
however, inconsistent with the antioxidant effects of the carotenoid that was shown in this study.
On the other hand, Kotake-Nara et al. (2005) reported that the induced apoptosis is not accompanied
by the production of ROS and caused by the loss of mitochondrial membrane potential [53]. It is
assumed that oxidative stress is linked to the initiation and promotion of cancer [25]. ROS might lead
to DNA damages and hence lead to uncontrolled cell proliferation and decreased apoptosis in cancer
cells. On the other hand, antitumor drugs often function by producing ROS that induce oxidative
stress in tumor cells and lead to cell death [54]. The role of antioxidants in tumor therapy is therefore a
controversial issue. Some studies show that antioxidants can promote the outcome of therapy, while
others show negative effects [54,55].
In summary, we were able to show antioxidant and antiproliferative but no anti-inflammatory
effects of the carotenoid fucoxanthin extracted from the microalgae P. tricornutum. Fucoxanthin was
able to inhibit the oxidative burst in human PMLs, scavenge radicals and increase the GSH to GSSG
ratio. Additionally, the metabolic activity was decreased, and apoptosis increased by the carotenoid.
This leads to the conclusion that fucoxanthin or the whole microalgae biomass, including fucoxanthin
in high amounts, could be considered in nutrition in order to ameliorate the effects of diseases linked to
oxidative stress. Additionally, fucoxanthin could help to support traditional cancer treatment because
of its beneficial health effects. Human trials are needed in future to further support these suggestions.
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